XNCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xencor Inc (XNCR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is weak, with significant YoY declines in revenue, net income, and EPS. Analysts have downgraded the stock, citing execution challenges and a lack of immediate catalysts. While technical indicators show some bullish momentum, the lack of positive news, weak financials, and neutral sentiment from hedge funds and insiders suggest that this stock may not be the best choice for long-term investment at this time.
The technical indicators show some bullish momentum. The MACD is positively expanding, and the moving averages (SMA_5 > SMA_20 > SMA_200) are bullish. However, the RSI is neutral at 68.045, and the stock is trading near its resistance levels (R1: 12.672, R2: 13.113).
NULL identified. No recent news or significant positive events to act as catalysts.
Weak financial performance in Q4 2025 with significant YoY declines in revenue (-59.67%), net income (-87.56%), and EPS (-87.67%). Analysts have downgraded the stock, citing execution challenges and a lack of immediate catalysts. Hedge funds and insiders are neutral, and there is no recent congress trading data.
In Q4 2025, revenue dropped to $28.24M (-59.67% YoY), net income dropped to -$6.65M (-87.56% YoY), and EPS dropped to -$0.09 (-87.67% YoY). Gross margin remained stable at 100%.
Analysts have downgraded the stock recently. JPMorgan downgraded Xencor to Neutral from Overweight, lowering the price target to $13 from $18, citing execution challenges and a lack of immediate catalysts. Barclays and BofA have slightly higher price targets ($27 and $20, respectively), but their updates are based on broader biotech trends rather than company-specific strengths.
